Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91(12), 4769-4775 (2006). (Pubitemid 44917305)
Kunwar S, Wilson CB. Pediatric pituitary adenomas. J. Clin. Endocrinol. Metab. 84(12), 4385-4389 (1999).
Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J. Clin. Endocrinol. Metab. 84(12), 4317-4323 (1999).
Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev. Neurother. 8(4), 563-574 (2008).
Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol, 4, 97-126 (2009).
Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. J. Intern. Med. 266(1), 5-18 (2009).
Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103(42), 15558-15563 (2006). (Pubitemid 44625631)
Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia J. Clin. Endocrinol. Metab. 92(8), 3321-3325 (2007).
Valdes-Socin H, Poncin J, Stevens V, Stevenaert A, Beckers A. Adénomes hypophysaires familiaux isolés non liés avec la mutation somatique NEM-1. Suivi de 27 patients. Ann. Endocrinol. (Paris) 61, 301 (2000).
Valdes-Socin H, Jaffrain Rea ML, Tamburrano G et al. Familial isolated pituitary tumors: clinical and molecular studies in 80 patients. Presented at: 84th Annual Meeting of the Endocrine Society, San Francisco, CA, USA, 19-22 June 2002.
Daly AF, Jaffrain-Rea ML, Beckers A. Clinical and genetic features of familial pituitary adenomas. Horm. Metab. Research 37 (6), 347-354 (2005). (Pubitemid 41008768)
Beckers A. Familial isolated pituitary adenomas. J. Intern. Med. 255(6), 698 (2004).
Daly AF, Jaffrain-Rea ML, Ciccarelli A et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab. 91(9), 3316-3323 (2006). (Pubitemid 44402097)
Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777), 1228-1230 (2006). (Pubitemid 43801151)
Daly AF, Van Bellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab. 92(5), 1891-1896 (2007).
Barlier A, Vanbellinghen JF, Daly AF et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 92(5), 1952-1955 (2007).
Cazabat L, Libè R, Perlemoine K et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 157(1), 1-8 (2007). (Pubitemid 47162559)
Georgitsi M, De Menis E, Cannavò S et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol. (Oxf.) 69(4), 621-627 (2008).
Beckers A, Vanbellinghen J-F, Boikos S et al. Germline AIP, MEN1, PRKAR1A, CDKN1B (p27Kip1) and CDKN2C (p18INK4c) gene mutations in a large cohort of pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic features. Presented at: 90th Annual Meeting of the Endocrine Society, San Francisco, CA, USA, 15-18 June 2008.
Tichomirowa MA, Daly AF, Barlier A et al. High incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas. Presented at: 91st Annual Meeting, Endocrine Society Washington, DC, USA, 10-13 June 2009.
Tichomirowa MA, Daly AF, Pujol J et al. An analysis of the role of cyclin dependent kinase inhibitor 1B (CDKN1B) gene mutations in 86 families with familial isolated pituitary adenomas (FIPA). Presented at: 91st Annual Meeting, Endocrine Society Washington, DC, USA, 10-13 June 2009.
Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur. J. Endocrinol. 157(4), 371-382 (2007). (Pubitemid 350018439)
Daly AF, Tichomirowa MA, Ebeling TML et al. An international collaborative study of the clinical characteristics and therapeutic responses in 92 pituitary adenoma patients with mutations of the aryl hydrocarbon receptor interacting protein gene. Presented at: 11th International Pituitary Congress Washington, DC, USA, 13-15 June 2009.
Jaffrain-Rea ML, Angelini M, Gargano D et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 16(3), 1029-1043 (2009).
Georgitsi M, Raitila A, Karhu A et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA 104(10), 4101-4105 (2007). (Pubitemid 47181585)
Leontiou CA, Gueorguiev M, van der Spuy J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 93(6), 2390-2401 (2008). (Pubitemid 351831563)
